Vertaling van "annual " (Nederlands → Frans) :

Annual report 2007” originated as a trainee’s report by Ann Eeckhout, head of the Communication & Scientific Support service, with the valuable cooperation of colleagues from the FAMHP.
Annual report 2007” originated as a trainee’s report by Ann Eeckhout, head of the Communication & Scientific Support service, with the valuable cooperation of colleagues from the FAMHP.

A MEDICINES AGENCY UNDER CONSTRUCTION Annual report 2007
A MEDICINES AGENCY UNDER CONSTRUCTION Annual report 2007

Reactions and events reported in 2006 were analysed and summarized in a first annual report which gives an overview of the notifications, the most important findings and a number of recommendations ●● In 2007 a total of 848 reactions and events
Reactions and events reported in 2006 were analysed and summarized in a first annual report which gives an overview of the notifications, the most important findings and a number of recommendations ●● In 2007 a total of 848 reactions and events

haemovigilance data and monitoring their implementation ●● The first annual report of the Haemovigilance Centre was published in 2007 Since November 2005, hospitals and blood establishments have been required to report to the Belgian Centre for Haemovigilance of the FAMHP serious reactions during the collection or administration of blood components and serious events relating to the quality or safety of blood components.
haemovigilance data and monitoring their implementation ●● The first annual report of the Haemovigilance Centre was published in 2007 Since November 2005, hospitals and blood establishments have been required to report to the Belgian Centre for Haemovigilance of the FAMHP serious reactions during the collection or administration of blood components and serious events relating to the quality or safety of blood components.

In this first “annual report”, we have chosen to describe the transition from the DG Medicinal Products of the FPS Public Health to an autonomous medicines agency and provide more details about a number of activities in 2007.
In this first “annual report”, we have chosen to describe the transition from the DG Medicinal Products of the FPS Public Health to an autonomous medicines agency and provide more details about a number of activities in 2007.

In 2007 it issued its first annual report and the external audit report to which it is subject (www.mdeon.be).
In 2007 it issued its first annual report and the external audit report to which it is subject (www.mdeon.be).

This report exists in Dutch, French and English The electronic version of this annual report 2007 is available on the FAMHP’s website www.fagg.be - www.afmps.be / Medicines / FAGG
This report exists in Dutch, French and English The electronic version of this annual report 2007 is available on the FAMHP’s website www.fagg.be - www.afmps.be / Medicines / FAGG

See note 20 in the Group’s Consolidated Financial Statements in the 2009 Annual Report for a summary of major legal proceedings. The following is a non-exhaustive list relating to some cases reported in the 2009 Annual Report and includes information as of the 2009 fourth quarter:
Pour un résumé des litiges majeurs, prière de consulter la note 20 des Comptes consolidés du Groupe figurant dans le rapport annuel 2009.La liste suivante, non exhaustive, passe en revue quelquesuns des cas cités dans le Rapport annuel 2009 et contient les informations disponibles au quatrième trimestre 2009.

The average annual dividend increased by 11.7% in CHF, while the annual total shareholder return since 1996 increased by 9%.
Depuis cette date, la hausse moyenne du dividende a été de 11,7% par an en francs suisses, tandis que le rendement annuel total pour les actionnaires a augmenté de 9%.

In particular, as discussed in notes 4 and 11 of the 2009 Annual Report, investments in associated companies and intangible assets (including goodwill and acquired In-Process Research & Development projects) are reviewed for impairment at least annually, or whenever an event or decision occurs that raises concern about their balance sheet carrying value.
Comme l’indiquent également les notes 4 et 11 du Rapport annuel 2009, les investissements dans les entreprises associées et les immobilisations incorporelles (y compris le goodwill et les projets acquis qui sont intégrés dans le processus de recherche et développement) font l’objet d’un test de dépréciation au moins une fois par an ou dès lors qu’un événement ou une décision les concernant suscitent des doutes quant à leur valeur inscrite au bilan.